Erbulozole

Erbulozole
Clinical data
Other names	Erbuzole
Identifiers
CAS Number	124784-31-2;
PubChem CID	9934372;
ChemSpider	8110000;
UNII	78XGN2K5RX;
Chemical and physical data
Formula	C24H27N3O5S
Molar mass	469.56 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCOC(=O)NC1=CC=C(C=C1)SC[C@H]2CO[C@](O2)(CN3C=CN=C3)C4=CC=C(C=C4)OC;
	InChI InChI=1S/C24H27N3O5S/c1-3-30-23(28)26-19-6-10-22(11-7-19)33-15-21-14-31-24(32-21,16-27-13-12-25-17-27)18-4-8-20(29-2)9-5-18/h4-13,17,21H,3,14-16H2,1-2H3,(H,26,28)/t21-,24+/m1/s1; Key:KLEPCGBEXOCIGS-QPPBQGQZSA-N;
	(verify)

Erbulozole (R55104) is a congener of the microtubule inhibitor tubulozole. It is undergoing phase I clinical trials as a chemotherapeutic agent.^[1]

Synthesis

Erbulozole synthesis: Lednicer book 6 (Drugs of the Future citation).

^ Van Belle SJ, Distelmans W, Vandebroek J, Bruynseels J, Van Ginckel R, Storme GA (1993). "Phase I trial of erbulozole (R55104)". Anticancer Research. 13 (6B): 2389–91. PMID 8135472.

Distelmans W, VanGinckel P, Heeres J, Van der Veken LJ (1991). "Erbulozole. Antineoplastic, Microtubule inhibitor". Drugs Future. 16 (6): 577.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.